Clinical Trials for: somatropin recombinant
Efficacy and Safety Evaluation of Recombinant Human Growth Hormone (r-hGH), Saizen®, on a Population of Children With Hypochondroplasia, Treated at Least 3 Years or Until Near Final Height, When Applicable, in Comparison With a Historic Cohort of Non-treated Children
Status: Active, not recruiting Condition: Hypochondroplasia
Recombinant Human Growth Hormone (RH-GH) For Accelerating Immune Reconstitution Post Unrelated Cord Blood Transplant
Status: Terminated Condition: Allogeneic Stem Cell Transplantation
Recombinant Human Growth Hormone During Rehabilitation From Traumatic Brain Injury.
Status: Recruiting Condition: Traumatic Brain Injury
rHGH and Intestinal Permeability in Intestinal Failure
Status: Active, not recruiting Condition: Short Bowel Syndrome
A Trial to Evaluate the Correlation Between Spontaneous Catch-up Growth, Clinical Response to Saizen (Recombinant Human Growth Hormone, r-hGH) and Gene Expression Profiling in Children Small for Gestational Age (SGA)
Status: Terminated Condition: Infant, Small for Gestational Age
Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance
Status: Completed Condition: HIV-Associated Lipodystrophy Syndrome; Insulin Resistance; HIV Infections; Metabolic Syndrome X; Body Weight Changes
Safety and Efficacy Trial of Serostim® in the Treatment of Subjects With Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
Status: Completed Condition: Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS); Human Immunodeficiency Virus Infections
Cool.Click™ Adolescent Transition Study: Study of Saizen® in Subjects With Childhood-onset Growth Hormone Deficiency
Status: Completed Condition: Childhood-onset Growth Hormone Deficiency; Pituitary Dwarfism
Effect of Cytokines on Growth of Children With Chronic Kidney Failure
Status: Suspended Condition: Chronic Renal Insufficiency
Effect of Recombinant Human Growth Hormone (rhGH) on Abdominal Fat and Cardiovascular Risk in Obese Girls
Status: Active, not recruiting Condition: Obesity
Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Litigation for: SOMATROPIN
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||Type||RLD||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Patented / Exclusive Use|
|INJECTABLE;SUBCUTANEOUS||020604||Feb 11, 2005||DISCN||No||<disabled>|
|INJECTABLE;INJECTION||021597||Dec 1, 2003||RX||Yes||5,898,030||<disabled>||Y|
|INJECTABLE;INJECTION||021597||Dec 1, 2003||DISCN||No||<disabled>|
|INJECTABLE;INJECTION||021905||Apr 19, 2007||RX||No||<disabled>|
|This preview shows a limited data set|
Complete access is available with a Subscription
Export unavailable in trial.
Subscribe for complete access.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639